# ISGIDAR

VOL. 16, NO. 1 FEBRUARY 1990

# INTERNATIONAL STUDY GROUP INVESTIGATING DRUGS AS REINFORCERS

### CORRESPONDENCE

#### ABOUT ISGIDAR:

Dr. Harriet de Wit Department of Psychiatry The University of Chicago 5841 S. Maryland Chicago, IL 60637 312-702-1537

### ABOUT ISGIDAR NEWSLETTER:

Dr. Richard A. Meisch
Department of Psychiatry
The University of Texas
Health Science Center at Houston
1300 Moursund
Houston, TX 77030
713-794-1440

## ISGIDAR SCIENTIFIC MEETING -- 1990

The annual ISGIDAR meeting will again be held as a satellite session of the Committee on Problems of Drug Dependence meeting, which this year is being held in Richmond, Virginia. The ISGIDAR meeting will be on Sunday, June 10. Registration will begin at 8:30 a.m. (\$15.00) and paper presentations will begin at 9:00 a.m. The business meeting will follow the paper presentations.

To present a paper at the ISGIDAR meeting, send a 300-word abstract by April 15, 1990 to Harriet de Wit at the address listed above. Please note that papers submitted to ISGIDAR should not also be presented at CPDD. The amount of time available for each talk will depend on the number of papers submitted but will not be less than 20 minutes.

#### MESSAGE FROM THE PRESIDENT

Since a major focus of much of the research conducted by ISGIDAR members is in the area of abuse liability testing, it may be of interest to many of you that the Food and Drug Administration (FDA) has recently begun to develop guidelines for assessing abuse liability, using both preclinical and clinical procedures. These procedures have evolved out of research conducted by many of our colleagues, and by present and former ISGIDAR members over the past 20 years. In developing the guidelines, the FDA is recognizing the validity and usefulness of laboratory measures of the reinforcing effects of drugs as indicators of abuse liability. Notably, this recognition extends to studies with human subjects as well as to those using laboratory animals. While it is understood that the laboratory techniques must continually be improved and refined, the recent dialogue between the FDA and researchers represents a milestone in the growth and

development of the field of behavioral pharmacology.

#### ANNUAL MEETING

May I remind members that the deadlines for ISGIDAR student travel award applications and ISGIDAR scientific presentation submissions are approaching (both due April 15). Attendance at the 1990 meeting is likely to be quite high because of the many behavioral pharmacologists in the Richmond/Baltimore/Washington area. So I urge you to submit your abstracts (and travel award applications) early so that we can plan the meeting and accommodate as many presentations as possible.

#### NOMINATIONS FOR MEMBERSHIP

Nominations for new members to ISGIDAR should be submitted to me before April 1, so that a ballot can be mailed out 60 days prior to the annual meeting.

# A MESSAGE FROM NANCY ATOR, VICE-PRESIDENT (ANIMAL USE)

# Status of U. S. Congressional Legislation and Animal Regulations Pertaining to the Use of Animals in Research--Nancy A. Ator

Legislation: On November 20, 1989, the Senate passed an amended version of S.727, "The Animal Research Facilities Protection Act," introduced by Senator Howell Heflin of Alabama. This act makes it a federal crime to steal, destroy or make unauthorized use of research animals, equipment, or data. The House of Representatives now must enact companion legislation H.R. 3270 (introduced by Rep. Stenholm of Texas), and conflicts between the two bills must be resolved in conference committee before the legislation can become law. The Stenholm bill is broader than the Heflin bill, because it applies to all animal research facilities, including those not federally funded, and to farm animal facilities. H.R. 3270 was referred to the House Agriculture Committee with 45 cosponsors, including the Committee Chairman, Senator de la Garza of Texas, but no further action has been taken. I would like to encourage you to write to your congressional representative urging support for H.R. 3270.

Senate bill S.891 introduced in May of 1989 by Senator Harry Reid of New York would prohibit the Food and Drug Administration from considering the results of the Draize test or LD50 tests unless the Secretary determined that no suitable alternatives were available. This bill was referred to the Senate Committee on Commerce, Science and Transportation, and hearings by the Commerce Subcommittee (Consumer) began on November 8. No action has been taken on the companion legislation in the House (H.R. 1676).

Six other pieces of legislation that should be of special interest or concern to researchers using animal subjects were introduced in the House of Representatives (none in the Senate). All were referred to committee, but no further action had been taken by adjournment. A bill which U. S. ISGIDAR members may want to support is: H.R. 3349 (Rep. H. Waxman, D-CA) Health Facilities Protection and Primate Center Rehabilitation Act. Those bills which ISGIDAR members may be concerned about include: H.R. 560 (Rep. R. Torricelli, D-NJ) Information Dissemination and Research Accountability Act; H.R. 2345 (Rep. C. Rose, D-NC) Standing Bill (i.e., allowing anyone to sue on his own behalf or the behalf of any animal to compel enforcement of the Animal Welfare Act); H.R. 2596 (Rep. Smith, R-NH) Transfer of the "Silver Spring Monkeys"; H.R. 2766 (Rep. Towns, D-NY) an amendment to the Animal Welfare Act to include mice, rats and birds within the definition of animals covered under the Act; and H.R. 3223 (Rep. C. Rose, D-NC), Animal Welfare Improvements Act of 1989. Copies of these bills may be obtained by writing to the House Document Room, H-226,

# U. S. Capitol, Washington, D. C. 20515.

Animal Care Regulations: Parts I and II of the revised USDA animal care regulations went into effect October 30, 1989. These regulations went through two revisions in response to the unprecedented numbers of public comments received. Part I consists of definitions and Part II now primarily concerns requirements on institutions which sponsor animal research, including the functions of the Institutional Animal Care and Use Committee (IACUC). Items of specific concern to ISGIDAR that were changed in the final rules include: (1) The prohibition against using an animal "in more than one major operative procedure from which it is allowed to recover" unless approved on a case-by-case basis was revised to allow for exception if "justified for scientific reasons by the principal investigator in writing" (presumably in the protocol submitted to the IACUC). (2) The prohibition of "deprivation of food or water" for the purpose of training animals was revised to add the phrase "Provided, however: That the short-term withholding of food or water from animals, when specified in an IACUC-approved activity. . . is allowed by these regulations." Write to REAC, APHIS, USDA, Room 206, 6505 Belcrest Road, Hyattsville, MD 20782 to obtain copies of the final rules.

Part III of the regulations contained specific requirements for animal housing and care, particularly having to do with the psychological well-being of captive primates and exercise for dogs. In response to comments received during the public comment period ending in July, 1989, Part III is being completely revised and is unlikely to be published in the next 6 to 9 months.

#### 1990 TRAVEL AWARD: STUDENT PAPER COMPETITION

ISGIDAR will again sponsor a Student Paper Competition Award for a new investigator to present a paper on drug self-administration research. Up to \$500 in reasonable and documented travel costs will be paid to the winner to attend the meeting of the Committee on Problems of Drug Dependence, 1990 to present a paper at the ISGIDAR satellite session. Payment will be made upon submission of travel receipts to the ISGIDAR Treasurer. Those who did not receive the award, but who did receive good reviews will be encouraged to present their papers at the ISGIDAR meeting.

ELIGIBILITY: Applicants must be enrolled in a graduate program and be working toward a doctorate or have received their doctorate within the last five years (after June 1, 1985).

Applicants who are not ISGIDAR members must be sponsored by an ISGIDAR member.

The research to be reported at ISGIDAR must not already be published.

MANUSCRIPT REQUIREMENTS: Papers should not be more than 10 pages excluding figures and references.

The length and scope of the paper should be consistent with a 20-25 minute slide presentation.

Please include paper title, name, address, phone number and author's signature on the cover page of the manuscript.

The signature and typed name of the author's sponsor should also appear on the cover page after a statement indicating that the applicant made a significant scientific contribution to the research.

Submit four copies, double-spaced.

REVIEW: Each manuscript will be independently reviewed by the ISGIDAR officers for originality,

scientific contribution, sound methodology and clarity of the manuscript.

Blind review is possible upon request.

Reviewers will not participate in the review of papers from their own institution.

Submit manuscripts to

Dr. Harriet de Wit Department of Psychiatry University of Chicago 5841 S. Maryland Chicago, IL 60637

DEADLINE FOR SUBMISSION: April 15, 1990

#### POST-DOCTORAL/RESEARCH ASSOCIATE POSITION

The Drug Abuse Research Center and the Human Behavioral Pharmacology Laboratory at the University of Chicago have an opening for a post-doctoral research associate. A variety of research opportunities are available, involving both human and laboratory animal studies on the behavioral and biological effects of abused drugs (e.g., drug self-administration and drug discrimination studies, studies on neurotoxicity and metabolic effects of abused drugs, and (human) studies on behavioral effects of antidepressant drugs). For information contact Harriet de Wit (312-702-1537) or Bill Woolverton (312-703-6360).

#### ISGIDAR BIBLIOGRAPHY

Listing of recent publications or manuscripts in press on the behavioral pharmacology of drugs of abuse by ISGIDAR members:

RA = published, reprints available IP = in press SU = submitted NA = published, reprints not available

Dr. Robert L. Balster Department of Pharmacology and Toxicology Box 613 Medical College of Virginia Richmond, VA 23298-0613

Balster, R.L. Pharmacological effects of cocaine relevant to its abuse. In Clouet, D., Ashgar, K., and Brown, R. (Eds), Mechanisms of Cocaine Abuse and Toxicity, National Institute on Drug Abuse Research Monograph No. 88, DHHS Publication (ADM) 88-1585. Washington, D.C.: U.S. Government Printing Office, 1988, pp. 1-13. (NA)

- Balster, R.L. Drug as chemical stimuli. <u>In Colpaert, F.C., and Balster, R.L.</u> (Eds), <u>Transduction Mechanisms of Drug Stimuli</u> Berlin: Springer-Verlag, 1988, pp. 3-11.
- Balster, R.L. Substitution and antagonism in rats trained to discriminate (+)-N-allylnormetazocine from saline. <u>Journal of Pharmacology and Experimental Therapeutics</u> 249: 749-756, 1989. (RA)
- Beardsley, P.M., and Balster, R.L. Evaluation of antagonists of the discriminative stimulus and response rate effects of phencyclidine. <u>Journal of Pharmacology</u> and Experimental Therapeutics 244: 34-40, 1988. (RA)
- Balster, R.L., and Willetts, J. Receptor mediation of the discriminative stimulus properties of phencyclidine and sigma-opioid agonists. <u>In Colpaert, F.C., and Balster, R.L.</u> (Eds), <u>Transduction Mechanisms of Drug Stimuli</u> Berlin: Springer-Verlag, 1988, pp. 122-135.
- Knisely, J.S., Beardsley, P.M., Aceto, M.D., Balster, R.L., and Harris, L.S. Assessment of the abuse potential of acetorphan, an enkephalinase inhibitor. <u>Drug and Alcohol Dependence</u> 23: 143-151, 1989. (RA)
- Porter, J.H., Wiley, J.L., and Balster, R.L. Effects of phencyclidine-like drugs on punished behavior in rats. <u>Journal of Pharmacology and Experimental Therapeutics</u> 248: 997-1002, 1989. (RA)
- Rees, D.C., and Balster, R.L. Attenuation of the discriminative stimulus properties of ethanol and oxazepam, but not of pentobarbital, by Ro 15-4513 in mice. <u>Journal of Pharmacology and Experimental Therapeutics</u> 244: 592-598, 1988. (RA)
- Slifer, B.L., and Balster, R.L. Phencyclidine-like discriminative stimulus effects of the stereoisomers of alpha- and beta-cyclazocine in rats. <u>Journal of Pharmacology and Experimental Therapeutics</u> 244: 606-612, 1988. (RA)
- Thurkauf, A., Zenk, P.C., Balster, R.L., May, E.L., George, C., Carroll, F.I., Mascarella, S.W., Rice, K.C., Jacobson, A.E., and Mattson, M.V. Synthesis, absolute configuration, and molecular modelling study of etoxadrol, a potent phencyclidine-like agonist. <u>Journal of Medicinal Chemistry</u> 31: 2257-2263, 1988. (NA)
- Willetts, J., and Balster, R.L. Phencyclidine-like discriminative stimulus properties of MK-801 in rats. <u>European Journal of Pharmacology</u> 146: 167-169, 1988. (RA)
- Willetts, J., and Balster, R.L. The discriminative stimulus properties of <u>N</u>-methyl-<u>D</u>-aspartate antagonists in phencyclidine-trained rats. <u>Neuropharmacology</u> 27: 1249-1256, 1988. (RA)
- Willetts, J., and Balster, R.L. Pentobarbital-like discriminative stimulus effects of N-methyl-D-aspartate antagonists. <u>Journal of Pharmacology and Experimental Therapeutics</u> 249: 438-443, 1989. (RA)

Dr. Harriet de Wit Department of Psychiatry University of Chicago 5841 S. Maryland Ave. Chicago, IL 60637

de Wit, H., J. Pierre, J., and Johanson, C.E.. Assessing pentobarbital preference in normal volunteers using a cumulative dosing procedure. Psychopharmacology 99: 416-421, 1989. (RA)

de Wit, H., and McCracken, S.G. Ethanol self-administration in males with and without an alcoholic first-degree relative. <u>Alcoholism: Clinical and Experimental Research</u> 14: 63-70, 1990. (RA)

Dr. Richard W. Foltin
Department of Psychiatry and Behavioral Science
The Johns Hopkins School of Medicine
600 N. Wolfe St., Houck E-2
Baltimore, MD 21205

Foltin, R.W. Effects of anorectic drugs on the topography of feeding behavior in baboons. <u>Journal of Pharmacology and Experimental Therapeutics</u> 249: 101-109, 1989. (RA)

Foltin, R.W., and Fischman, M.W. Ethanol and cocaine interactions in humans: Cardiovascular consequences. <u>Pharmacology Biochemistry and Behavior</u> 31: 877-883, 1988. (RA)

Foltin, R.W., and Fischman, M.W. Food intake in baboons: Effects of *d*-amphetamine and fenfluramine. <u>Pharmacology Biochemistry and Behavior</u> 31: 585-592, 1988. (RA)

Foltin, R.W., Fischman, M.W., and Byrne, M.F. Effects of diazepam on food intake in baboons. <u>Psychopharmacology</u> 97: 443-447, 1989. (RA)

Foltin, R.W., Fischman, M.W., Brady, J.V., Capriotti, R.M., and Emurian, C.S. The regularity of smoked marijuana self-administration. <u>Pharmacology Biochemistry</u> and Behavior 32: 483-486, 1989. (RA)

Foltin, R.W., Fischman, M.W., Pedroso, J.J., and Pearlson, G.D. Repeated intranasal cocaine administration: Lack of tolerance to pressor effects. <u>Drug and Alcohol Dependence</u> 22: 169-177, 1988. (RA)

Foltin, R.W., McEntee, M.A., Capriotti, R.M., Pedroso, J.J., and Fischman, M.W. Effect of cocaine on the task-elicited physiological response. <u>Pharmacology</u> <u>Biochemistry and Behavior</u> 31: 387-391, 1988. (RA)

Foltin, R.W., and Moran, T.H. Food intake in baboons: Effect of a long-acting cholecystokinin agonist. <u>Appetite</u> 12: 145-152, 1989. (RA)

Dr. Jonathan B. Kamien Alcohol and Drug Abuse Research Center Harvard Medical School 115 Mill St. Belmont, MA 02178

Kamien, J.B. Excel and Relist: Manage and format your references. <u>The Active Window</u> 5: 30-32, 1988. (RA)

Kamien, J.B., and Woolverton, W.L. A pharmacological analysis of the discriminative stimulus properties of *d*-amphetamine in rhesus monkeys. <u>Journal of Pharmacology and Experimental Therapeutics</u> 248: 938-946, 1989. (RA)

Kamien, J.B., and Woolverton, W.L. Buspirone blocks the discriminative stimulus effects of apomorphine in monkeys. <u>Pharmacology Biochemistry and Behavior</u> 35: 117-120, 1990. (RA)

Kamien, J.B., and Woolverton, W.L. Failure of SCH 23390 to function as a discriminative stimulus in rats. <u>Pharmacology Biochemistry and Behavior</u> 34: 337-340, 1989. (RA)

Madras, B.K., Kamien, J.B., Fahey, M.A., Canfield, D.R., Milius, R.A., Saha, J.K., Neumeyer, J.L., and Spealman, R.D. N-modified fluorophenyltropane analogs of cocaine with high affinity for [<sup>3</sup>H]cocaine binding sites. <u>European Journal of Pharmacology</u>, 1989, submitted. (SU)

Dr. Richard A. Meisch Dept. of Psychiatry UTHSC-H 1300 Moursund Houston, TX 77030-3406

Meisch, R.A., George, F.R., and Lemaire, G.A. Orally delivered cocaine as a reinforcer for rhesus monkeys. <u>Pharmacology Biochemistry and Behavior</u> 35: 245-249, 1990. (RA)

Meisch, R.A., and Lemaire, G.A. Reinforcing effects of a pentobarbital-ethanol combination relative to each drug alone. <u>Pharmacology Biochemistry and Behavior</u> 35: 443-450, 1990. (RA)

Dr. William L. Woolverton
Department of Pharmacological
and Physiological Sciences
University of Chicago
947 E. 58th Street
Chicago, IL 60637

Corwin, R.L., Woolverton, W.L., and Schuster, C.R. Effects of cholecystokinin, d-amphetamine and fenfluramine in rats trained to discriminate 3-hours from 22-hours of food deprivation. <u>Journal of Pharmacology and Experimental Therapeutics</u>, in press. (IP)

- Kamien, J.B., and Woolverton, W.L. Buspirone blocks the discriminative stimulus effects of apomorphine in monkeys. <u>Pharmacology Biochemistry and Behavior</u> 35: 117-120, 1990. (RA)
- Kamien, J.B., and Woolverton, W.L. Failure of SCH 23390 to function as a discriminative stimulus in rats. <u>Pharmacology Biochemistry and Behavior</u> 34: 337-340, 1989. (RA)
- Kleven, M.S., Anthony, E.W., Goldberg, L.I., and Woolverton, W.L. Blockade of the discriminative stimulus effects of cocaine in rhesus monkeys with the D1 dopamine antagonist SCH 23390. <u>Psychopharmacology</u> 95: 427-429, 1988. (RA)
- Kleven, M.S., Anthony, E.W., and Woolverton, W.L. Pharmacological characterization of the discriminative stimulus effects of cocaine in rhesus monkeys. <u>Journal of Pharmacology and Experimental Therapeutics</u>, submitted. (SU)
- Kleven, M.S., and Woolverton, W.L. The effects of bromocriptine and desipramine on behavior maintained by cocaine or food presentation in rhesus monkeys. <u>Psychopharmacology</u>, 1990, in press. (IP)
- Kleven, M.S., and Woolverton, W.L. Effects of continuous infusion of the D1 antagonist SCH 23390 on behavior maintained by cocaine or food presentation in rhesus monkeys. <u>Behavioural Pharmacology</u>, submitted. (SU)
- Kleven, M.S., Woolverton, W.L., and Seiden, L.S. Lack of long-term monoamine depletions following repeated or continuous exposure to cocaine. <u>Brain</u> Research Bulletin 21(2): 1988. (RA)
- Vanover, K.V., Wenger, G.R., and Woolverton, W.L. Self-administration of the isomers of pentobarbital and secobarbital by rhesus monkeys. <u>Pharmacology</u> <u>Biochemistry and Behavior</u> 34: 669-671, 1989. (RA)
- Williams, J.E.G., Sutherland, J.V., and Woolverton, W.L. Evaluation of the interaction between D1 and D2 receptors in a drug discrimination paradigm. Behavioral and Neural Biology, 1990, in press. (IP)
- Woolverton, W.L., and Kleven, M.S. Evidence for cocaine dependence in monkeys following a prolonged period of exposure. <u>Psychopharmacology</u> 94: 288-291, 1988. (RA)
- Woolverton, W.L., and Kleven, M.S. Multiple dopamine receptors and the behavioral effects of cocaine. In: <u>Mechanisms of Cocaine Abuse and Toxicity</u>, ed. by D. Clouet, K. Asghar, and R. Brown. National Institute on Drug Abuse, Research Monograph No. 88, Washington, D.C.: U.S. Government Printing Office, 1988, pp. 160-184. (NA)
- Woolverton, W.L., and Nader, M.A. Experimental evaluation of the reinforcing effects of drugs. In: M.W. Adler and A. Cowan (Eds), <u>Testing and Evaluation of Drugs of Abuse</u>. Alan R. Liss, Inc., New York, N.Y., 1990. (NA)
- Zacny, J.P., Virus, R.M., Kleven, M.S., and Woolverton, W.L. Tolerance and cross-tolerance to 3,4-methylenedioxymethamphetamine (MDMA), methamphetamine and methylenedioxyamphetamine. <u>Pharmacology</u>

Biochemistry & Behavior, 1990, in press. (IP)

Zacny, J.P., and Woolverton, W.L. Discriminative stimulus properties of local anesthetics in *d*-amphetamine- and pentobarbital-trained pigeons. Pharmacology Biochemistry & Behavior 33: 527-531, 1989. (RA)

Dr. James P. Zacny Department of Psychiatry University of Chicago 5841 S. Maryland Ave. Chicago, IL 60637

- Evans, S., Zacny, J., and Johnson, J. A three-choice discrimination between amphetamine, fenfluramine and saline. <u>Pharmacology Biochemistry and Behavior</u>, in press. (IP)
- Zacny, J.P. Behavioral aspects of alcohol-tobacco interactions. In: <u>Recent Developments in Alcoholism</u>, Plenum Publishing Corporation, in press. (IP)
- Zacny, J.P. Discriminative stimulus effects of H<sub>1</sub>-anithistamines in cocaine-trained pigeons. <u>Behavioural Pharmacology</u>, submitted.
- Zacny, J.P., and de Wit, H. Effects of food deprivation on subjective responses to d-amphetamine in humans. <u>Pharmacology Biochemistry & Behavior</u> 34: 791-795, 1989. (RA)
- Zacny, J.P. and de Wit, H. Effects of food deprivation on cigarette consumption in humans. British Journal of Addiction, in press. (IP)
- Zacny, J.P. and de Wit, H. Effects of food deprivation on responses to marijuana in humans. <u>Behavioural Pharmacology</u>, in press. (IP)
- Zacny, J.P., and Chait, L.D. Breathhold duration and response to marijuana smoke <u>Pharmacology Biochemistry & Behavior</u> 33: 481-484, 1989. (RA)
- Zacny, J.P., and Stitzer, M.L. Cigarette brand-switching: Effects on smoke exposure and smoking behavior. <u>The Journal of Pharmacology and Experimental Therapeutics</u> 246: 619-627, 1988. (RA)
- Zacny, J.P., Virus, R.M., Kleven, M.S., and Woolverton, W.L. Tolerance and cross-tolerance to 3,4-Methylenedioxymethamphetamine (MDMA), methamphetamine and methylenedioxyamphetamine. <u>Pharmacology</u> <u>Biochemistry & Behavior</u>, 1990, in press. (IP)
- Zacny, J.P., and Woolverton, W.L. Discriminative stimulus properties of local anesthetics in *d*-amphetamine- and pentobarbital-trained pigeons. Pharmacology Biochemistry & Behavior 33: 527-531, 1989. (RA)

IS.	GID	ΔR	BI	IBL	IO	GR	Δ	PH۱	/ F	OR	M
$\cdot$	<b>UID</b>	~11	-		$\cdot$	un	~,			$\mathbf{v}_{11}$	141

(	RA)	Published,	reprints	available

- (IP) In Press, reprints will be mailed after publication
- (NA) Reprints unavailable
- (SU) Submitted

In submitting your entries, use any useful format. Mail this form to:

Dr. Richard A. Meisch Dept. of Psychiatry UTHSC-H 1300 Moursund Houston, TX 77030-3406

Note: If the response cost is less to just mail a copy of the preprint or reprint, please feel free to do so with ISGIDAR written on the envelope or the paper itself.

Address for reprints:			
		an man air an mar	

Citations (in alphabetical order)